The global pharmaceutical contract sales outsourcing (CSO) market size accounted for USD 10.90 billion in 2024, grew to USD 11.85 billion in 2025, and is expected to be worth around USD 25.09 billion by 2034, poised to grow at a CAGR of 8.69% between 2024 and 2034. The North America pharmaceutical contract sales outsourcing (CSO) market size is predicted to increase from USD 3.92 billion in 2024 and is estimated to grow at the fastest CAGR of 8.84% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pharmaceutical Contract Sales Outsourcing (CSO) Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pharmaceutical Contract Sales Outsourcing (CSO) Market, by Service, 2024-2034
8.1.1. Personal Promotion
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Non-personal Promotion
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. Pharmaceutical Contract Sales Outsourcing (CSO) Market, by Therapeutic Area, 2024-2034
9.1.1. Cardiovascular Disorders
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Oncology
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Metabolic Disorders
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Neurology
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Orthopedic Diseases
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Infectious Diseases
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Service (2021-2034)
10.1.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Service (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Service (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Service (2021-2034)
10.2.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Service (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Service (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Service (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Service (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Service (2021-2034)
10.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Service (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Service (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Service (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Service (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Service (2021-2034)
10.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Service (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Service (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Service (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Service (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Service (2021-2034)
10.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Service (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Service (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
11.1. IQVIA Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Syneos Health Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Parexel International Corporation
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Pharmaceutical Product Development (PPD) LLC
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. inVentiv Health Inc. (part of Syneos Health)
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. ICON plc
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Publicis Touchpoint Solutions, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. PRA Health Sciences, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. The Medical Affairs Company (TMAC)
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Ashfield Healthcare Communications Group (part of UDG Healthcare plc)
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample